Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers developed and validated a rapid and robust chromatographic method to assess the concentration of Minoxidil and Finasteride in a new topical formulation for alopecia, demonstrating its ability to distinguish between different types of formulations using in vitro diffusion data.

In this study, the researchers reported that while both propylene glycol and sodium lauryl sulfate enhanced finasteride's skin deposition, ethanol was the only effective enhancer of finasteride's permeation through the skin.

This review discusses the progress in research on topical formulations for treating alopecia, highlighting potential advantages of advanced formulation technologies but reporting no new clinical results.

This study reported that a solid lipid nanoparticle-based gel formulation, specifically optimized for psoriasis, improved drug loading capacity and release properties using high-pressure homogenization, suggesting its potential efficacy as a topical treatment.

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.

This study suggests that novel lipid nanoparticle formulations may be suitable for delivering anti-alopecia compounds like minoxidil and finasteride, although their skin penetration was limited.

This study discusses the limitations of current FDA-approved treatments for androgenic alopecia, noting significant sexual side effects with oral finasteride and formulation challenges with topical minoxidil, and highlights the potential of nanocarriers to improve drug delivery to hair follicles.

This study found that a chitosan-decorated finasteride nanosystem exhibited satisfactory drug release and retention in rat skin, suggesting it could enhance topical delivery for androgenic alopecia treatment.

Topical finasteride is promising for hair loss with minimal side effects but needs more research and approval.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.

In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This study found that a topical formulation with nanostructured lipid carriers containing finasteride significantly restored hair follicles in androgenetic alopecia-induced rats without systemic absorption, suggesting its potential for safer and effective AGA treatment.

This study reviewed the publication trends and key findings on alternative therapies for androgenetic alopecia, highlighting the increasing research interest in dutasteride and nontopical minoxidil, while noting a lack of high-quality trials for nontopical minoxidil formulations.

This review discusses the pathogenesis and treatment of androgenetic alopecia, highlighting genome associations and newer topical formulations, but reports no new clinical results.

This study reported that solid lipid nanoparticles of finasteride decorated with chitosan enhanced drug retention in skin layers, suggesting potential application in treating androgenic alopecia and benign prostate hyperplasia with fewer side effects.

This abstract introduces androgenic alopecia as the most common form of non-cicatricial alopecia, which predominantly affects men but also has a significant occurrence in women; however, specific research results or conclusions about treatments or mechanisms are not reported in the summary.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This review discusses recent advancements in the development and use of polymer-based nanohydrogels for topical drug delivery, noting their potential to enhance drug loading, release control, and skin penetration for treating dermatological conditions.

This study found that finasteride-containing anionic liposomes enhanced skin retention and had moderate hair growth efficacy, suggesting potential for treating androgenetic alopecia with reduced systemic side effects.

This study found that a topical emulsion containing purified extracts of sidr leaves and roasted candlenut seeds significantly increased hair growth compared to the base and 2% minoxidil, potentially through their antioxidant and anti-inflammatory properties.

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.

This study explored microemulsion formulations for delivering finasteride through the skin, finding that higher water concentrations increased permeation, which may inform optimal transdermal delivery for treating androgenetic alopecia.

This article reviews treatment options for male-pattern and female-pattern hair loss, telogen effluvium, and alopecia areata, but provides no new clinical results; algorithmic management approaches are included.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This study found that Carthamus tinctorius exhibited the strongest 5α-reductase inhibitory and hair growth promoting activities among evaluated Thai herbs, suggesting potential for developing alternative hair loss treatments.